Home Protein Tyrosine Kinase BTK inhibitor Fenebrutinib (GDC-0853)

research use only

Fenebrutinib (GDC-0853) BTK inhibitor

Fenebrutinib (GDC-0853) is a potent, selective, and non-covalent bruton's tyrosine kinase (BTK) inhibitor. It has an Ki value of 0.91 nM for Btk with >100-fold selectivity over 3 off-targets (Bmx :153-fold, Fgr: 168-fold, Src:131-fold).

Fenebrutinib (GDC-0853) BTK inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 664.80

Purity & Quality Control

Batch: S842101 DMSO]8 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.91%
99.91

Related Products

Signaling Pathway

BTK Signaling Pathways

BTK Signaling Pathway

Mechanism of Action

Targets
BTK [1]
(Cell-free assay)		 BTK C481R [1]
(Cell-free assay)		 BTK C481S [1]
(Cell-free assay)		 BTK T474M [1]
(Cell-free assay)		 BTK T474I [1]
(Cell-free assay)
0.91 nM(Ki) 1.3 nM(Ki) 1.6 nM(Ki) 3.4 nM(Ki) 12.6 nM(Ki)

In vitro
In vitro

Fenebrutinib (GDC-0853), when tested at 1 μM against a broad panel of human kinase biochemical assays, inhibits only 3 of 286 off-target kinases. Based on the determined IC50 values, the selectivity for Btk is >100-fold against each of these 3 off-targets: Bmx (153-fold), Fgr (168-fold), and Src (131-fold). This compound blocks both B-cell BCR and monocyte FcγR signaling. In in vitro biochemical Btk enzyme assay, it displays an average residence time with Btk of 18.3 ± 2.8 hours. It blocks cellular autophosphorylation of WT Btk and the C481S mutant[1]. CLL (chronic lymphocytic leukemia) cells treated with GDC-0853 in vitro before BCR stimulation demonstrate reduced levels of BTK phosphorylation and diminished activation of downstream targets including PLCγ2, AKT, and ERK. It inhibits NF-κB–dependent transcription, reduces activation, and impairs migration. This compound lacks inhibition of EGFR and ITK in cellular system and does not affect T-cell receptor activation[3].
Kinase Assay Kinase selectivity
Fenebrutinib (GDC-0853) kinase selectivity is assessed at a concentration of 1 µM in a panel of up to 287 recombinant human kinase activity and binding assays, including cytoplasmic and receptor tyrosine kinases, serine/threonine kinases, and lipid kinases. The kinase activity assays measure peptide phosphorylation or ADP production while the binding assays monitored displacement of ATP sitebinding probes. The ATP concentrations used in the activity assays are typically within 2-fold of the experimentally determined apparent Michaelis constant (Kmapp) value for each kinase while the competitive binding tracer concentrations used in the binding assays are generally within 3-fold of the experimentally determined dissociation constant (Kd) values. This compound is tested in duplicate against each kinase and the mean % Inhibition values are reported. For kinases that are inhibited by close to or greater than 80% at the test concentration, 10-point inhibitor titrations using the same assays are carried out in order to determine the inhibitor concentrations that caused 50% inhibition (IC50).
Cell Research Cell lines CLL cells
Concentrations 1 μM
Incubation Time 48 hours
Method Cells are treated with 1 µM of the BTK inhibitor Fenebrutinib (GDC-0853) for 48 hours and measured for viability by flow cytometry.
Experimental Result Images Methods Biomarkers Images PMID
Western blot p-BTK / BTK / p-PLCγ2 / PLCγ2 / p-AKT / AKT / p-ERK / ERK S8421-WB1 30018078

In Vivo
In vivo

Fenebrutinib (GDC-0853) has moderate clearance of 27.4 mL/min/kg and excellent bioavailability (F=65%) in rats administered 0.2 mg/kg via intraperitoneal injection or 1 mg/kg PO. The plasma clearance is 27.4 mL/min/kg, the volume of distribution (Vd) is 5.42 L/kg and the plasma half-life (t1/2) is 2.2 h. This compound also demonstrates favorable PK properties in dogs. The 3.8-hour half-life (Clp 10.9 mL/min/kg, Vd 2.96 L/kg) and high oral bioavailability (85%) also enable attainment of sufficient exposures in dog toxicology studies. It is well tolerated in both rats and dogs and displays an overall favorable safety profile. It is useful in treating rheumatoid arthritis and other B-cell or myeloid cell mediated autoimmune diseases. In a single ascending dose (SAD) study (0.5 mg to 600 mg) and multiple ascending dose (MAD) study for 14 days (250 mg BID to 500 mg QD), it is very well tolerated with no severe adverse events, no safety signals, and no dose limiting toxicities. It is well absorbed and had linear, doseproportional pharmacokinetics[1]. In Sprague-Dawley (SD) rats, administration of this compound and other structurally diverse BTK inhibitors for 7 days or longer cause pancreatic lesions consisting of multifocal islet-centered hemorrhage, inflammation, fibrosis, and pigment-laden macrophages with adjacent lobular exocrine acinar cell atrophy, degeneration, and inflammation. Similar findings are not observed in mice or dogs at much higher exposures[2].
Animal Research Animal Models Sprague-Dawley, Wistar-Han and Fischer-344 rats (6 to 12 weeks old)
Dosages 5 or 10 mL/kg
Administration p.o.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05119569 Active not recruiting
Relapsing Multiple Sclerosis
Hoffmann-La Roche
 March 1 2022 Phase 2
NCT04586023 Active not recruiting
Relapsing Multiple Sclerosis
Hoffmann-La Roche
 March 24 2021 Phase 3
NCT04586010 Active not recruiting
Relapsing Multiple Sclerosis
Hoffmann-La Roche
 March 17 2021 Phase 3
NCT03693625 Terminated
Urticaria
Genentech Inc.
 September 27 2018 Phase 2
NCT03596632 Completed
Healthy Participants
Hoffmann-La Roche
 July 27 2018 Phase 1

References
  • https://pubmed.ncbi.nlm.nih.gov/29457982/
  • https://pubmed.ncbi.nlm.nih.gov/27821712/
  • https://pubmed.ncbi.nlm.nih.gov/30018078/

Chemical Information

Molecular Weight 664.80 Formula

C37H44N8O4
CAS No. 1434048-34-6 SDF --
Synonyms N/A
Smiles CC1CN(CCN1C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C4=C(C(=NC=C4)N5CCN6C7=C(CC(C7)(C)C)C=C6C5=O)CO)C8COC8

Storage and Stability

Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 8 mg/mL ( (12.03 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.